DKK 0.18
(-2.17%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.02 DKK | -124.44% |
2022 | 0.09 DKK | -3.81% |
2021 | 0.10 DKK | 109.42% |
2020 | -1.03 DKK | -1356.86% |
2019 | -0.07 DKK | 77.91% |
2018 | -0.32 DKK | -4100.0% |
2017 | 0.01 DKK | 114.44% |
2016 | -0.06 DKK | 57.38% |
2015 | -0.13 DKK | 95.67% |
2014 | -3.00 DKK | 96.79% |
2013 | -93.59 DKK | -227.7% |
2012 | -28.56 DKK | -133.14% |
2011 | -12.25 DKK | -665.63% |
2010 | -1.60 DKK | 88.7% |
2009 | -14.16 DKK | 87.13% |
2008 | -109.99 DKK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.01 DKK | 44.88% |
2024 Q2 | -0.01 DKK | 18.57% |
2023 Q4 | -0.01 DKK | -195.35% |
2023 Q1 | -0.15 DKK | -1476.15% |
2023 Q2 | -0.00 DKK | 97.2% |
2023 Q3 | -0.00 DKK | -2.38% |
2023 FY | - DKK | -124.44% |
2022 Q4 | 0.01 DKK | 536.0% |
2022 FY | - DKK | -3.81% |
2022 Q2 | -0.00 DKK | 0.0% |
2022 Q3 | -0.00 DKK | 3.85% |
2021 FY | - DKK | 109.42% |
2020 FY | - DKK | -1356.86% |
2019 FY | - DKK | 77.91% |
2018 FY | - DKK | -4100.0% |
2017 FY | - DKK | 114.44% |
2016 Q1 | -0.02 DKK | 0.0% |
2016 FY | - DKK | 57.38% |
2016 Q2 | -0.01 DKK | 43.27% |
2015 FY | - DKK | 95.67% |
2015 Q4 | - DKK | 100.0% |
2015 Q3 | -0.04 DKK | 80.0% |
2015 Q2 | -0.20 DKK | -33.33% |
2015 Q1 | -0.15 DKK | 0.0% |
2014 Q4 | - DKK | 100.0% |
2014 Q1 | -2.18 DKK | 0.0% |
2014 FY | - DKK | 96.79% |
2014 Q2 | -0.69 DKK | 68.35% |
2014 Q3 | -0.06 DKK | 91.99% |
2013 Q2 | -41.96 DKK | -1377.46% |
2013 Q4 | - DKK | 100.0% |
2013 Q3 | -4.39 DKK | 89.54% |
2013 Q1 | -2.84 DKK | 0.0% |
2013 FY | - DKK | -227.7% |
2012 Q3 | -2.88 DKK | 13.51% |
2012 Q2 | -3.33 DKK | -72.54% |
2012 FY | - DKK | -133.14% |
2012 Q1 | -1.93 DKK | 0.0% |
2012 Q4 | - DKK | 100.0% |
2011 Q2 | -3.40 DKK | -0.59% |
2011 Q3 | -2.02 DKK | 40.59% |
2011 FY | - DKK | -665.63% |
2011 Q1 | -3.38 DKK | 0.0% |
2011 Q4 | - DKK | 100.0% |
2010 FY | - DKK | 88.7% |
2010 Q4 | - DKK | 100.0% |
2010 Q3 | -1.56 DKK | -168.97% |
2010 Q2 | -0.58 DKK | -205.26% |
2010 Q1 | -0.19 DKK | 0.0% |
2009 Q2 | -4.71 DKK | 0.0% |
2009 Q3 | -0.07 DKK | 98.58% |
2009 FY | - DKK | 87.13% |
2009 Q4 | - DKK | 100.0% |
2008 FY | - DKK | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
ALK-Abelló A/S | 2.20 DKK | 101.036% |
Bavarian Nordic A/S | 19.23 DKK | 100.119% |
Genmab A/S | 66.64 DKK | 100.034% |
Gubra A/S | -2.93 DKK | 99.222% |
Novo Nordisk A/S | 18.67 DKK | 100.122% |
Orphazyme A/S | -0.74 DKK | 96.919% |
Zealand Pharma A/S | -12.44 DKK | 99.817% |